These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29434961)

  • 1. Effect and molecular mechanism of mTOR inhibitor rapamycin on temozolomide-induced autophagic death of U251 glioma cells.
    Li B; Zhou C; Yi L; Xu L; Xu M
    Oncol Lett; 2018 Feb; 15(2):2477-2484. PubMed ID: 29434961
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Knockdown of Nrf2 enhances autophagy induced by temozolomide in U251 human glioma cell line.
    Zhou Y; Wang HD; Zhu L; Cong ZX; Li N; Ji XJ; Pan H; Wang JW; Li WC
    Oncol Rep; 2013 Jan; 29(1):394-400. PubMed ID: 23128449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-30a increases the chemosensitivity of U251 glioblastoma cells to temozolomide by directly targeting beclin 1 and inhibiting autophagy.
    Xu J; Huang H; Peng R; Ding X; Jiang B; Yuan X; Xi J
    Exp Ther Med; 2018 Jun; 15(6):4798-4804. PubMed ID: 29805498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib inhibits growth and sensitizes glioma to temozolomide (TMZ) via down-regulating the FOXM1-Survivin axis.
    Tang JH; Yang L; Chen JX; Li QR; Zhu LR; Xu QF; Huang GH; Zhang ZX; Xiang Y; Du L; Zhou Z; Lv SQ
    Cancer Commun (Lond); 2019 Dec; 39(1):81. PubMed ID: 31796105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-asarone inhibited cell growth and promoted autophagy via P53/Bcl-2/Bclin-1 and P53/AMPK/mTOR pathways in Human Glioma U251 cells.
    Wang N; Zhang Q; Luo L; Ning B; Fang Y
    J Cell Physiol; 2018 Mar; 233(3):2434-2443. PubMed ID: 28776671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of silencing S-phase kinase-associated protein 2 on chemosensitivity to temozolomide of human glioma cells U251.
    Liu Y; Tang ZG; Yang JQ; Zhou Y; Lin Y; Lv W; Wang GB; Li CL
    Am J Transl Res; 2019; 11(4):2470-2476. PubMed ID: 31105854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. All-trans retinoic acid enhances temozolomide-induced autophagy in human glioma cells U251 via targeting Keap1/Nrf2/ARE signaling pathway.
    Shi L; Li H; Zhan Y
    Oncol Lett; 2017 Sep; 14(3):2709-2714. PubMed ID: 28927033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of thalidomide to enhance cytotoxicity of temozolomide in U251-MG glioma cells in vitro.
    Gao S; Yang XJ; Zhang WG; Ji YW; Pan Q
    Chin Med J (Engl); 2009 Jun; 122(11):1260-6. PubMed ID: 19567134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of temozolomide on livin and caspase-3 in U251 glioma stem cells.
    Li G; Zhang H; Liu Y; Kong L; Guo Q; Jin F
    Exp Ther Med; 2015 Mar; 9(3):744-750. PubMed ID: 25667622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic Suppression of Glioblastoma Cell Growth by Combined Application of Temozolomide and Dopamine D2 Receptor Antagonists.
    Liu Z; Jiang X; Gao L; Liu X; Li J; Huang X; Zeng T
    World Neurosurg; 2019 Aug; 128():e468-e477. PubMed ID: 31048057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential pro-apoptotic effects of synthetic 4-thiazolidinone derivative Les-3288, doxorubicin and temozolomide in human glioma U251 cells.
    Коbylinska LI; Klyuchivska OY; Grytsyna II; Finiuk N; Panchuk RR; Starykovych MO; Lehka L; Lesyk RB; Zіmenkovsky BS; Stoika RS
    Croat Med J; 2017 Apr; 58(2):150-159. PubMed ID: 28409498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-Asarone promotes Temozolomide's entry into glioma cells and decreases the expression of P-glycoprotein and MDR1.
    Wang N; Zhang Q; Ning B; Luo L; Fang Y
    Biomed Pharmacother; 2017 Jun; 90():368-374. PubMed ID: 28380412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dihydroartemisinin increases temozolomide efficacy in glioma cells by inducing autophagy.
    Zhang ZS; Wang J; Shen YB; Guo CC; Sai KE; Chen FR; Mei X; Han FU; Chen ZP
    Oncol Lett; 2015 Jul; 10(1):379-383. PubMed ID: 26171034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Toxic effects of Vitamin C combined with temozolomide on glioma cells and its mechanism].
    Chen MS; Zhao HK; Cheng YY; Yuan ZH; Zhang YL
    Zhongguo Ying Yong Sheng Li Xue Za Zhi; 2020 Nov; 36(6):616-621. PubMed ID: 33719269
    [No Abstract]   [Full Text] [Related]  

  • 15. The Inhibition of microRNA-128 on IGF-1-Activating mTOR Signaling Involves in Temozolomide-Induced Glioma Cell Apoptotic Death.
    Chen PH; Cheng CH; Shih CM; Ho KH; Lin CW; Lee CC; Liu AJ; Chang CK; Chen KC
    PLoS One; 2016; 11(11):e0167096. PubMed ID: 27893811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of temozolomide-induced antitumour effects on glioma cells.
    Shen W; Hu JA; Zheng JS
    J Int Med Res; 2014 Feb; 42(1):164-72. PubMed ID: 24326954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.
    Kanzawa T; Bedwell J; Kondo Y; Kondo S; Germano IM
    J Neurosurg; 2003 Dec; 99(6):1047-52. PubMed ID: 14705733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The synergistic therapeutic effect of temozolomide and hyperbaric oxygen on glioma U251 cell lines is accompanied by alterations in vascular endothelial growth factor and multidrug resistance-associated protein-1 levels.
    Lu XY; Cao K; Li QY; Yuan ZC; Lu PS
    J Int Med Res; 2012; 40(3):995-1004. PubMed ID: 22906272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status.
    Chong DQ; Toh XY; Ho IA; Sia KC; Newman JP; Yulyana Y; Ng WH; Lai SH; Ho MM; Dinesh N; Tham CK; Lam PY
    BMC Cancer; 2015 Apr; 15():255. PubMed ID: 25886314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
    Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
    Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.